Dechra Pharmaceuticals PLC Total Voting Rights (7015Q)
01 Marzo 2021 - 12:32PM
UK Regulatory
TIDMDPH
RNS Number : 7015Q
Dechra Pharmaceuticals PLC
01 March 2021
1 March 2021
Dechra(R) Pharmaceuticals PLC
(Dechra or the Company)
LEI: 213800J4UVB5OWG8VX82
Total Voting Rights
In conformity with DTR 5.6.1R, the Company notifies the market
of the following:
As at the date of this announcement, the Company's issued share
capital consists of 108,159,144 ordinary shares with a nominal
value of 1 pence each (Ordinary Shares), with voting rights. The
Company does not hold any Ordinary Shares in Treasury.
Therefore, the total number of Ordinary Shares with voting
rights is 108,159,144.
The above figure of 108,159,144 Ordinary Shares may be used by
shareholders in the Company as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change in their interest in, the share capital of
the Company under the FCA's Disclosure and Transparency Rules.
For further information, please contact:
Dechra Pharmaceuticals PLC
Telephone number: +44 (0) 1606 814730
Email: corporate.enquiries@dechra.com
About Dechra
Dechra is a global veterinary pharmaceuticals and related
products business. Our expertise is in the development,
manufacture, marketing and sales of high quality products
exclusively for veterinarians worldwide. The majority of Dechra's
products are focused on key therapeutic categories where we have
leading market positions, and many of our products are used to
treat medical conditions for which there is no other effective
solution or have a clinical or dosing advantage over competitor
products. For more information, please visit: www.dechra.com .
Trademarks
Trademarks appear throughout this document in italics. Dechra
and the Dechra "D" logo are registered trademarks of Dechra
Pharmaceuticals PLC.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRFFLFBFXLXBBB
(END) Dow Jones Newswires
March 01, 2021 06:32 ET (11:32 GMT)
Grafico Azioni Dechra Pharmaceuticals (LSE:DPH)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Dechra Pharmaceuticals (LSE:DPH)
Storico
Da Apr 2023 a Apr 2024